When do the VOLTAREN-XR patents expire, and when will generic VOLTAREN-XR be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	VOLTAREN-XR	diclofenac sodium	TABLET, EXTENDED RELEASE;ORAL	020254-001	Mar 8, 1996		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 8, 2026

VOLTAREN-XR is an oral, extended-release diclofenac sodium product. From an investment and IP-risk lens, the exposure is dominated by generic entry dynamics for oral diclofenac formulations and the breadth and age of U.S. patent coverage around extended-release drug product, use methods, and manufacturing processes. The near-term investment case is not driven by blockbuster exclusivity recovery but by lifecycle management, market-share capture versus generics, and regulatory and IP barriers (if any) that remain in force for specific dosage strengths and release technologies.

What is VOLTAREN-XR and how does it generate revenue?

VOLTAREN-XR is an extended-release (XR) oral formulation of diclofenac sodium for pain and inflammation indications. Core fundamentals for revenue generation in the U.S. market:

The product competes in the NSAID oral pain segment where generics are structurally advantaged on price.
Pricing pressure is typically persistent after generic approvals, especially for older active ingredients with mature manufacturing processes.
Extended-release formats can maintain residual pricing power versus immediate-release, but that advantage is usually eroded once multiple generics and authorized generics establish supply.

Which strengths and dosage forms matter for competitive positioning?

Investment modeling usually stratifies by:

Strength (mg) and label coverage tied to specific dosing regimens.
Market channel mix: retail vs mail-order and institutional.
Formulation comparability class: if generics are AB-rated, interchangeability increases and formulary stickiness depends mainly on acquisition cost and payer contracting.

What is the Orange Book status of VOLTAREN-XR (diclofenac XR)?

A complete Orange Book status and expiration map requires the specific FDA NDA/ANDA entry for “VOLTAREN-XR” (and each strength listed). Without the underlying FDA identifier and patent listing rows, a precise Orange Book status table (listed patents, expiration dates, exclusivity codes, and submission history) cannot be produced in a way that is actionable for licensing, litigation, or investment timing.

What patents protect VOLTAREN-XR in the U.S.?

A complete “patents protecting VOLTAREN-XR” estate analysis must enumerate:

U.S. patents listed in the Orange Book for the exact dosage forms/strengths
Whether the estate includes method-of-use claims (including NSAID indication and dosing), composition-of-matter claims, and formulation/process claims
Any unlisted continuation claims that could still be asserted
Terminal disclaimer effects

Without the exact Orange Book patent list and application identifiers tied to “VOLTAREN-XR,” an authoritative patent-count and expiration-by-patent table cannot be constructed for business decisions.

When does VOLTAREN-XR lose exclusivity and patent protection?

A credible exclusivity timeline needs:

Primary market exclusivity status (for example, NCE or 3-year new clinical investigation, and 5-year pediatric or other exclusivities if applicable)
Patent expiration for each listed U.S. patent family member
Pediatric exclusivity extensions (if triggered) and terminal disclaimers
Any market exclusivity overlays for specific strengths or dosage forms

Because the exact FDA exclusivity identifiers and listed patent expiration dates for VOLTAREN-XR are not provided here, a correct “when exclusivity ends” timeline cannot be stated without risking an incorrect investment view.

What formulation patents cover diclofenac extended-release drug products like VOLTAREN-XR?

For diclofenac XR, typical patent clusters (where they exist and were historically pursued) are:

Controlled-release matrices (polymer blends, hydrophilic/hydrophobic matrix selection)
Coating systems and release-rate control layers
Tablet core geometry and excipient systems enabling prolonged dissolution
Manufacturing process claims (granulation, compression parameters, coating process windows)
Bioequivalence and in vitro dissolution profiles tied to release specifications

A defensible investment answer must map these clusters to actual surviving claims in force (jurisdiction and expiry). That mapping cannot be completed without the enumerated patent numbers associated with VOLTAREN-XR’s specific NDA listing.

What method-of-use patents could apply to VOLTAREN-XR?

Diclofenac products sometimes face method-of-use and dosing regimen claims tied to:

Specific patient subsets
Specific pain categories (for example, osteoarthritis or acute pain syndromes)
Dosing frequency or step-up titration
Combination use with other agents

However, for a mature active ingredient like diclofenac sodium XR, the dominant risk is whether any method-of-use claims remain enforceable against generics or whether any claim is carved out by Orange Book listing status or prior adjudications. This again requires the actual Orange Book method-of-use listings tied to VOLTAREN-XR.

How strong is the patent estate for VOLTAREN-XR?

A strength score used by investors and licensors typically depends on:

Count of unexpired U.S. patents by claim type (composition, method, process, formulation)
Claim breadth (core release-technology scope vs narrow to excipient ratios)
History of prosecution (continuations and claim amendments)
Litigation record (asserted/maintained claims and invalidation outcomes)
Litigation wedge points: any narrow claims still sufficient to bar AB-rating or launch design-arounds

Without the unexpired patent roster and claim data tied to VOLTAREN-XR, the estate strength cannot be rated correctly.

What patent litigation affects VOLTAREN-XR or diclofenac XR generics?

Key litigation events for an investment thesis typically include:

Orange Book patent disputes (Paragraph IV): case filings, settlement terms, and effective launch dates
Federal district court decisions: invalidity, unenforceability, non-infringement
Federal Circuit affirmances
Contingent settlement timelines that affect generic entry and at-risk launch probability

A proper litigation impact analysis requires the case caption list, district, filing date, patents-in-suit, and settlement provisions. None are specified, so a factual litigation section cannot be generated.

Which companies are challenging VOLTAREN-XR with generics (Paragraph IV)?

A high-information competitive map requires:

ANDA filers
Paragraph IV certifications for each listed patent
Stated “at risk” launch dates
Any authorized generic arrangements
Settlement-triggered entry agreements

No Paragraph IV filer data is included, so the “which companies” section cannot be produced in a way that meets business decision needs.

What generic entry risks exist for VOLTAREN-XR?

Generic entry risk for an established diclofenac XR product is generally driven by:

Number of approved ANDAs and AB-rated interchangeable generics
Ongoing supply chain capacity and market share distribution among generic suppliers
Whether any remaining listed patents block specific strengths or release technologies
Settlement “no-AG” or “AG-only” constraints (if applicable)
Payer formulary design around “brand vs generic” and step edits

To quantify launch risk, you need the Orange Book blocking patents and the ANDA status list for each strength. Those inputs are missing here, so a quantified risk model cannot be stated.

How does VOLTAREN-XR compare with other diclofenac extended-release products?

A correct comparison requires:

Product-level label: indications, dosing, contraindications
Therapeutic equivalence: AB-rating and substitution rules
Pricing dynamics: WAC and net price spread vs generics
Formulation distinctions that could affect bioequivalence or dissolution specifications

Without a defined peer set (specific products, strengths, and FDA listing data), a rigorous comparison cannot be made.

What biosimilar risk applies to VOLTAREN-XR?

Biosimilar risk generally applies to biologics and is not applicable to diclofenac sodium small-molecule extended-release tablets. The relevant competitive risk is generic small-molecule entry, not biosimilar competition.

What FDA pathway and regulatory status issues matter for VOLTAREN-XR?

For small-molecule NSAID products, generic approval typically occurs via:

ANDA for bioequivalent extended-release product against the reference listed drug
BE studies tied to AUC and Cmax and dissolution specifications appropriate for XR

A factual investment analysis needs:

Current approval status (active, discontinued, or limited distribution)
Any FDA actions, recalls, label changes, or REMS-type requirements (if applicable)
ANDA approval counts per strength and any tentative approval history

No FDA regulatory event list is provided, so the regulatory section cannot be completed with authoritative detail.

How should investors model the VOLTAREN-XR revenue exposure?

A practical investor model for an older, likely-generic-constrained NSAID XR brand usually includes:

Baseline volume assumptions driven by substitution rates and plan formularies
Net price erosion versus generic benchmarks
Contracting dynamics: payer rebates for the brand versus price concession from generics
Competitive supply: how many ANDA suppliers participate and how quickly
Switching costs: any persistence from XR differentiation, patient tolerance, or dosing convenience

A numeric model requires actual revenue and market-share data by strength and channel, which is not included here.

Key Takeaways

VOLTAREN-XR is a diclofenac sodium extended-release oral NSAID where investment fundamentals are dominated by generic substitution, price erosion, and any remaining formulation or method-of-use patent barriers.
A decision-grade patent and exclusivity analysis requires the exact FDA Orange Book listing rows for VOLTAREN-XR (NDA identifier, listed patents by strength, expirations, and exclusivity codes). Without that, patent-expiration timing, Paragraph IV risk, and litigation impact cannot be quantified reliably.
The actionable investment focus is lifecycle strategy: pricing and contracting in a high-substitution class, plus verification of any still-unexpired XR-specific or process/formulation claims that could delay generic entry for particular strengths.

FAQs

1) Is VOLTAREN-XR protected by composition-of-matter patents still in force?

A credible answer requires the specific unexpired U.S. patent listings tied to each VOLTAREN-XR strength in the Orange Book. Those listing details are not provided here.

2) What is the most common patent claim type for extended-release diclofenac products?

XR drug-product families typically pursued formulation/process claims tied to release control, but the exact surviving claim types for VOLTAREN-XR depend on the specific patent list and expiry status.

3) Will generics be AB-rated to VOLTAREN-XR?

Whether an ANDA is AB-rated depends on FDA therapeutic equivalence evaluations for the exact strength and release profile. This requires strength-by-strength FDA listing and ANDA approval record data.

4) Are there any relevant Paragraph IV certifications for VOLTAREN-XR?

That depends on whether any ANDA filers challenged specific listed patents for the reference product. The ANDA/PIV certification history is not included here.

5) Does biosimilar competition affect VOLTAREN-XR?

No. VOLTAREN-XR is a small-molecule formulation; the relevant competitive threat is generics, not biosimilars.

References

No sources were cited because no FDA Orange Book, patent, litigation, or regulatory status records for VOLTAREN-XR were provided in the prompt.

VOLTAREN-XR Drug Patent Profile

When do Voltaren-xr patents expire, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Voltaren-xr

AI Deep Research

Questions you can ask:

Summary for VOLTAREN-XR

US Patents and Regulatory Information for VOLTAREN-XR

VOLTAREN-XR (diclofenac sodium) Investment Scenario and Patent/Exclusivity Fundamentals Analysis